

MIF (11): sc-130329

BACKGROUND

Macrophage migration inhibitory factor, known as MIF or glycosylation-inhibiting factor, is a secreted, homotrimeric, pro-inflammatory cytokine that modulates macrophage and T cell function and is an important regulator of host response to infection. MIF is expressed at sites of inflammation, which suggests that it plays a role in regulating macrophage function in host defense. MIF is produced by the pituitary gland and found in monocytes, macrophages, differentiating immunological cells in the eye lens and brain, and fibroblasts. Elevated levels of MIF protein are detected in the plasma of patients with severe sepsis or septic shock, a condition where MIF influences endotoxin shock by enhancing the production of other inflammatory cytokines including tumor necrosis factor- α (TNF α), interleukin-1 (IL-1) and interferon- γ (IFN- γ). MIF promotes the systemic inflammatory response by counter-regulating glucocorticoid-mediated inhibition of immune-cell activation and pro-inflammatory cytokine production. MIF may mediate tissue destruction through the induction of proteinases.

REFERENCES

- Weiser, W.Y., et al. 1989. Molecular cloning of a cDNA encoding a human macrophage migration inhibitory factor. *Proc. Natl. Acad. Sci. USA* 86: 7522-7526.
- Paralkar, V., et al. 1994. Cloning the human gene for macrophage migration inhibitory factor (MIF). *Genomics* 19: 48-51.
- Bernhagen, J., et al. 1994. Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). *Biochemistry* 33: 14144-14155.
- Lubetsky, J.B., et al. 1999. Pro-1 of macrophage migration inhibitory factor functions as a catalytic base in the phenylpyruvate tautomerase activity. *Biochemistry* 38: 7346-7354.
- Onodera, S., et al. 1999. High expression of macrophage migration inhibitory factor in the synovial tissues of rheumatoid joints. *Cytokine* 11: 163-167.
- Benigni, F., et al. 2000. The proinflammatory mediator macrophage migration inhibitory factor induces glucose catabolism in muscle. *J. Clin. Invest.* 106: 1291-1300.
- Calandra, T., et al. 2000. Protection from septic shock by neutralization of macrophage migration inhibitory factor. *Nat. Med.* 6: 164-170.

CHROMOSOMAL LOCATION

Genetic locus: MIF (human) mapping to 22q11.23.

SOURCE

MIF (11) is a mouse monoclonal antibody raised against recombinant MIF of human origin.

PRODUCT

Each vial contains 200 μ g IgG_{2a} kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

APPLICATIONS

MIF (11) is recommended for detection of MIF of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 μ g per 100-500 μ g of total protein (1 ml of cell lysate)] and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for MIF siRNA (h): sc-37137, MIF shRNA Plasmid (h): sc-37137-SH and MIF shRNA (h) Lentiviral Particles: sc-37137-V.


Molecular Weight of MIF: 13 kDa.

Positive Controls: MIF (h2): 293T Lysate: sc-129140, HL-60 whole cell lysate: sc-2209 or Jurkat whole cell lysate: sc-2204.


RECOMMENDED SUPPORT REAGENTS

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-IgG κ BP-HRP: sc-516102 or m-IgG κ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker™ Molecular Weight Standards: sc-2035, UltraCruz® Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunoprecipitation: use Protein A/G PLUS-Agarose: sc-2003 (0.5 ml agarose/2.0 ml).

DATA



MIF (11): sc-130329. Western blot analysis of MIF expression in non-transfected: sc-117752 (A) and human MIF transfected: sc-129140 (B) 293T whole cell lysates.



MIF (11): sc-130329. Western blot analysis of MIF expression in non-transfected: sc-117752 (A) and human MIF transfected: sc-129141 (B) 293T whole cell lysates.

SELECT PRODUCT CITATIONS

- Li, Q., et al. 2019. Downregulation of microRNA-451 improves cell migration, invasion and tube formation in hypoxia-treated HUVECs by targeting MIF. *Mol. Med. Rep.* 20: 1167-1177.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.



See **MIF (D-2): sc-271631** for MIF antibody conjugates, including AC, HRP, FITC, PE, and Alexa Fluor® 488, 546, 594, 647, 680 and 790.